As a leader in the design and delivery of care-based, oncology research, George Clinical has access to significant global investigator networks, experienced project teams, oncology experts, and scientific leaders to design and deliver oncology trials, with the latest immunotherapies, to the highest scientific standards. By accessing some of the world’s most experienced medical, scientific and operational teams in oncology research, George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research and thus demonstrates product value in terms of clinical effectiveness, specialized cohorts, and tolerability.
Exceptional medical, scientific and operational expertise makes George Clinical an ideal partner for clinical trials throughout North America, Europe and the Asia-Pacific.
George Clinical has extensive experience in all phases of oncology programs including, MTD, early Phase I, II and III and late-phase trials, health economics and outcomes research. Our full services team is comprised of scientific leaders, doctors, nurses, biostatisticians and trial management professionals that work together to ensure timely delivery of quality trial data on time and on budget.
George Clinical offers a unique combination of scientific leadership and operational capabilities to design and deliver studies for sponsors, no matter the complexity. George Clinical offers:
George Clinical’s extensive experience in oncology trials provides sponsors with the confidence that their oncology trial will be delivered on time, on budget and to the highest scientific standards.
Our clinical trial services in oncology clinical trials include:
Dr. Wabnitz has extensive leadership and experience with a unique combination of clinical medicine, pharmacology, and industry drug development experience. He is Consultant Physician at Royal Adelaide Hospital (FRACP), Australia. He is a passionate expert in Phase I / First in Human clinical trials and drug development, pharmacology, chemistry and toxicology. He is qualified in regulatory submissions, HREC reviews/approvals, clinical trial design and execution, medical monitoring and extensive clinical trial networks within Australia, Asia, EU and the USA.
Dr. Wabnitz’s primary driving force is to bring quality therapies with appropriate risk/benefit to patients in most need, predominately oncology patients. He has significant experience in “hands-on” preclinical development (PK/TK/DDI/Metabolism/Toxicology), and has acted as Principal Investigator and Medical Monitor on numerous Phase I and II trials as well as being the Medical Director of an Australian Phase I unit. Dr. Wabnitz is an Advanced Training Specialist in Medical Oncology who has authored 22 peer-reviewed journal articles on biologicals, peptides, proteins, drug development and cancer / Medical Oncology research.
Dr. Thomas’ focus is on the application of genomic technologies to the understanding and management of cancer. He is Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research, and a National Health & Medical Research Council (NHMRC) L3 Investigator. He is CEO of Omicron, a non-profit company with a national precision medicine program for patients with advanced and early onset cancers, which he established in 2019. He is also Conjoint Professor, UNSW, Sydney.
Dr. Thomas is an internationally recognized leader in his field and is especially interested in precision oncology and clinical trials, somatic and germline cancer genomics, and sarcomas and cancer in young adults. He founded the Australasian Sarcoma Study Group, a national research organization, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. He leads the International Sarcoma Kindred Study, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. In 2018, he was President of the Connective Tissue Oncology Society, the peak international body in his field.
Dr. Khasraw’s research interests include biomarker development and design of innovative clinical trials to improve outcomes for patients with primary and metastatic cancers of the central nervous systems. He is a Neuro-oncologist, tenured professor of medicine and neurobiology and Deputy Director of the Center for Cancer Immunotherapy at Duke University, USA. He is interested in translating research into new therapies and at Duke, is tasked with speeding up clinical research and translation for scientists across all departments and tumor sites.
Dr. Khasraw is leading several clinical and translational programs with significant laboratory collaborations and is the principal investigator on first-in-human Phase I immunotherapy clinical trials in solid tumors. He serves as the Clinical Trials TRACK co-lead for Society of Neuro-oncology (SNO) and as an advisor and grant reviewer for several non-profits and patient advocacy groups. He is a Fellow of the Royal Australasian College of Physicians and an Elected Fellow of the Royal College of Physicians (UK) and an Honorary Professor at the University of Sydney (Australia).
Susan is responsible for U.S. project and clinical operations, including project management, study startup, monitoring and site management services. With over 25 years in clinical research, she brings experience in all phases of clinical trials, multiple therapeutic areas including over 12 years in oncology, and key leadership roles in clinical operations and financial management. She has helped develop or improve services for multiple U.S. Contract Research and Site Management organizations, as well as a national oncology site network. Her work with global and cross-functional teams brings added value to the George Clinical team as the Global Head of Therapeutic Strategy, Oncology.
Dr. Schwartzberg’s research interests include breast cancer, supportive care and developmental therapeutics. He is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno; and a founding Chief Medical Officer at OneOncology.. He was recently involved with genomic profiling of advanced cancer and is interested in visionary approaches to clinical research and oncology science. He divides his time between patients in the clinic and conducting clinical research trials and programmatic development.
A renowned expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg is a member of the Board of Directors for the National Comprehensive Cancer Network and is the founding editor-in-chief of the journal Community Oncology. He is also the current editor-in-chief of the Practice Update Oncology website and serves on the editorial board for both the Journal of Supportive Oncology and the ASCO Post.
Dr. Boccia’s research interest is in cancers of the blood and blood-forming tissues as well as solid tumors, such as those seen in bladder cancer. He is Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Maryland, and Clinical Associate Professor of Medicine at Georgetown University in Washington, DC. He also serves as the Chief Medical Officer for the International Oncology Network (ION). He conducts research in exploring the latest advances in colorectal cancer treatment and offers individualized care to patients with focus on multi-modal treatment regimens.
Dr. Boccia has studied and published cancer patients’ supportive care data on cytokine support for chemotherapy-induced anemia and leukopenia, and cytoprotective agents; specifically, amifostine (Ethyol) administration schedules designed to reduce side effects and improve safety. He is a member of numerous professional societies including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation.
Dr Jeremy Teoh’s research interests are in bladder and prostate cancer including urinary biomarkers for bladder cancer and androgen deprivation therapy for prostate cancer. He is Assistant Dean (External Affairs) and Assistant Professor of the Faculty of medicine, The Chinese University of Hong Kong. He is also Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong and Vice-Chair of the Young Fellows Chapter of the Hong Kong Academy of Medicine, and has been the Director of the Lions Kidney Educational Centre & Research Foundation since 2016.
Dr. Teoh developed a global consensus statement to standardize the en bloc resection approach and is studying the urinary biomarkers, tumour heterogeneity and molecular classification of bladder cancer. He has received numerous research grants with a total funding of more than HKD 30 million and has been serving as a member for several advisory boards for prostate cancer and bladder cancer. Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and believes that social media plays an important role in the modern era of medicine.
Dr. VanderWalde’s primary research is in melanoma, immunotherapy and targeted therapies based on immune markers and aberrations in cancer genetics. He is Vice President of Clinical Development, Caris Life Sciences, and Senior Medical Director, George Clinical. A thought leader in melanoma and clinical trial design and implementation, he has collaborated on advisory boards with many of the nation’s thought leaders and top experts in the field and previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma.
As Former Director of Research at West Cancer Center and Research Institute, Dr. VanderWalde was responsible for managing the portfolio of all clinical trials. He is the former Director of Precision Oncology at OneOncology.
Dr. Loong’s clinical interests include sarcoma medical oncology, neuro-oncology, thoracic oncology and experimental therapeutics (Phase I clinical trials). He is based in Hong Kong and holds conjoint appointments of Clinical Assistant Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase I Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. He has conducted over 50 oncology Phase I, II and III trials as either a Principal Investigator or Co-Investigator and is interested in actively helping to develop further capacity for oncology research within the APAC region.
Dr. Loong obtained his medical degree from The University of Hong Kong and completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a special focus on Experimental Therapeutics. He is a recipient of the European Cancer Congress Fellowship Grant (2013), the ASCO Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers, Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.
Dr. Pluard’s research is focused on new targeted therapies of breast cancer. He is Medical Director, Saint Luke’s Cancer Institute and Koontz Center for Advanced Breast Cancer, Kansas City, MO. Previously, he was Associate Professor of Medicine and Clinical Director of Breast Oncology at Washington University Siteman Cancer Center in St. Louis. He specializes in offering comprehensive care including advanced genomic and immunotherapy treatments to women with metastatic breast cancer and advises patients on participating in clinical trials for leading-edge treatments.
Dr. Pluard leads a team at St. Luke’s Cancer Institute focused on the comprehensive care of women with breast cancer where every woman’s tumor is genetically analyzed to understand what is driving their cancer. He emphasizes the importance of in-depth communication with patients taking a fully holistic approach to their treatment options. With his work at Saint Luke’s, Koontz Center and in clinical trials, Dr. Pluard strives to help define care for all women with advanced breast cancer.